Thematic Exposure -- 6/10
Altria is the dominant US cigarette company (~45% retail share, Marlboro alone ~40%), operating in a
textbook oligopoly with extraordinary pricing power -- 8.4% net price realization in FY2025 and 63%+
smokable OCI margins. However, ~88% of revenue remains in combustible cigarettes, a category declining
at 8-10% annually (2-3x the historical rate). The smoke-free transition is failing: NJOY ACE is banned
and largely written down, and on! oral nicotine pouches are a distant #2 to ZYN with share eroding.
on! PLUS (national launch H1 2026) is the key catalyst but unproven at scale. The 6.45% dividend yield
provides a floor, but this is a managed decline with optionality, not a growth story.
Weight: 25%
Oligopoly Hard Gate: PASS -- Dominant US Cigarette Oligopoly
#1 US Cigarette Company (~45% Retail Share) -- Marlboro ~40% Alone -- 8.4% Net Price Realization -- 63%+ OCI Margins
The US cigarette market is a textbook oligopoly. Altria (PM USA) holds ~45% retail
share, with Marlboro alone at ~40% (39.8% in Q4 2025, down from 42.0% in Q1 2024). Reynolds American
(BAT subsidiary) holds ~25-27%, with the remainder fragmented among discount/generic brands.
Pricing power is exceptional: 8.4% net price realization in FY2025 even as volumes declined ~10%. Smokable adjusted OCI margins expanded to 63.4% for FY2025, up 1.8pp YoY. This is world-class margin for a consumer staples business, enabled by the consolidated market structure and Marlboro brand dominance.
However, the oligopoly is in a secularly declining category: FY2025 adjusted cigarette volume decline was -9.5% (industry: -8.0%), with ~2-3pp attributed to cross-category migration (primarily illicit e-vapor). Management sees moderation in H2 2025 as enforcement intensifies.
Oligopoly gate: PASS. Clear US oligopoly with dominant #1 position. The gate is passed -- but this is a declining oligopoly, which caps the thematic score.
Pricing power is exceptional: 8.4% net price realization in FY2025 even as volumes declined ~10%. Smokable adjusted OCI margins expanded to 63.4% for FY2025, up 1.8pp YoY. This is world-class margin for a consumer staples business, enabled by the consolidated market structure and Marlboro brand dominance.
However, the oligopoly is in a secularly declining category: FY2025 adjusted cigarette volume decline was -9.5% (industry: -8.0%), with ~2-3pp attributed to cross-category migration (primarily illicit e-vapor). Management sees moderation in H2 2025 as enforcement intensifies.
Oligopoly gate: PASS. Clear US oligopoly with dominant #1 position. The gate is passed -- but this is a declining oligopoly, which caps the thematic score.
Competitive Positioning -- US Cigarette Market Share
| Company | Retail Share | Key Brands | Competitive Dynamic |
|---|---|---|---|
| Altria (PM USA) | ~45% | Marlboro (~40%), Basic, L&M | Dominant #1. Marlboro slipping below 40% but Basic capturing discount growth |
| Reynolds American (BAT) | ~25-27% | Camel, Newport, Natural American Spirit | Distant #2. Newport strong in menthol segment |
| Liggett / Others | ~5-8% | Eagle 20s, various deep discount | Small players, primarily in deep discount |
| Deep Discount / Generic | Balance | Various | Fragmented, growing as price-sensitive smokers trade down |
Data from Daloopa and Altria Q4 2025 earnings. Marlboro at 39.8% in Q4 2025 marks a
psychological milestone below 40%, though total Altria share remains stable at ~45% via Basic deployment.
Marlboro Retail Share
39.8%
Q4 2025 -- below 40% for first time
Net Price Realization
+8.4%
FY2025 -- offsets volume decline
Smokable OCI Margin
63.4%
FY2025, +1.8pp YoY
Cig Volume Decline
-9.5%
FY2025 adjusted (industry: -8.0%)
Revenue Mix by Product Segment (FY2025)
| Segment | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | FY2025 | % of FY |
|---|---|---|---|---|---|---|
| Smokable Products | $4,622M | $5,357M | $5,387M | $5,119M | $20,485M | ~88% |
| Oral Tobacco Products | $654M | $753M | $689M | $706M | $2,802M | ~12% |
| E-vapor (NJOY) | -- | -- | -- | $21M | ~$21M | <1% |
| Total | $5,259M | $6,102M | $6,072M | $5,846M | $23,279M | 100% |
Data sourced from Daloopa.
~88% of revenue remains combustible cigarettes. Oral tobacco (including on!) is ~12%.
E-vapor (NJOY) is negligible after the NJOY ACE ITC ban.
Theme 1: Cigarette Cash Cow (Positive but Declining)
Marlboro Below 40% for First Time -- Basic Deployed in 30,000+ Stores -- 8.4% Price Realization Offsets Volume Losses
Marlboro retail share slipped below 40% for the first time (39.8% in Q4 2025), a psychological
milestone. However, total Altria cigarette share remains relatively stable at ~45% due to the
Basic discount brand strategy -- deployed in ~30,000+ stores and capturing >50%
of discount segment growth.
Pricing power remains exceptional: 8.4% net price realization in FY2025 more than offsets volume losses. Smokable adjusted OCI margins expanded to 63.4%, up 1.8pp YoY. The new import/export duty drawback arrangement with KT&G is an additional margin lever (payback <1 year per management).
The concern: Volume declines of 8-10% are materially worse than the historical 3-4%, driven by e-vapor competition. Q4 2025 showed improvement to -7.0% (industry: -6.5%), suggesting potential moderation as illicit e-vapor enforcement intensifies -- but the trend remains clearly negative.
Pricing power remains exceptional: 8.4% net price realization in FY2025 more than offsets volume losses. Smokable adjusted OCI margins expanded to 63.4%, up 1.8pp YoY. The new import/export duty drawback arrangement with KT&G is an additional margin lever (payback <1 year per management).
The concern: Volume declines of 8-10% are materially worse than the historical 3-4%, driven by e-vapor competition. Q4 2025 showed improvement to -7.0% (industry: -6.5%), suggesting potential moderation as illicit e-vapor enforcement intensifies -- but the trend remains clearly negative.
Theme 2: Oral Nicotine Pouches / on! (Mixed)
US Pouch Market Growth
+45%
YoY in Q1 2025, approaching $5B+
on! Retail Share (Total Oral)
7.7%
Q4 2025, down from 8.9% peak
ZYN Market Dominance
~66%
Of oral nicotine pouch market
ZYN vs on! Volume Gap
4.5:1
794M vs ~177M cans shipped (2025)
The US nicotine pouch market is the fastest-growing nicotine category (+45% YoY), but
on! is losing the share war to ZYN (Philip Morris). ZYN dominates at ~66% of the pouch
market; on! is a distant #2. Total oral tobacco retail share is collapsing: 29.6% in Q4 2025, down from
37.8% in Q1 2024, as Copenhagen/Skoal MST declines and ZYN growth dilute Altria share.
Key Catalyst: on! PLUS National Launch H1 2026
on! PLUS launched in 3 states in December 2025, with national rollout planned for
H1 2026. It has received FDA marketing granted orders -- a regulatory moat vs. illicit
competitors. Consumer feedback is positive on mouthfeel/comfort differentiation.
However, the competitive environment is intense: category prices are down 12% YoY while on! raised prices 3%. The 4.5:1 volume gap vs. ZYN (794M vs. ~177M cans) is daunting. on! PLUS is the potential catalyst but remains unproven at scale.
However, the competitive environment is intense: category prices are down 12% YoY while on! raised prices 3%. The 4.5:1 volume gap vs. ZYN (794M vs. ~177M cans) is daunting. on! PLUS is the potential catalyst but remains unproven at scale.
Theme 3: E-Vapor / NJOY (Negative)
NJOY ACE Banned (ITC Patent Ruling, March 2025) -- $1.3B Non-Cash Impairment -- Will NOT Return in 2026
The NJOY ACE was banned from the US market via an ITC patent ruling in March 2025. Management has
confirmed it will NOT return in 2026. Altria recorded $1.3B in non-cash
impairment charges in Q4 2025 ($873M goodwill + intangibles), largely writing down the
$2.75B NJOY acquisition.
E-vapor segment revenue was negligible ($21M in Q4 2025, the only reported quarter). NJOY had ~6.6% retail share of consumables before ACE removal. A modified ACE design has been completed but the pathway to market is unclear, and new JUUL litigation adds further uncertainty.
Broader context: ~70% of the US e-vapor market consists of illicit flavored disposables -- a regulatory mess that actually benefits Altria if enforcement intensifies (reducing cross-category migration from cigarettes).
E-vapor segment revenue was negligible ($21M in Q4 2025, the only reported quarter). NJOY had ~6.6% retail share of consumables before ACE removal. A modified ACE design has been completed but the pathway to market is unclear, and new JUUL litigation adds further uncertainty.
Broader context: ~70% of the US e-vapor market consists of illicit flavored disposables -- a regulatory mess that actually benefits Altria if enforcement intensifies (reducing cross-category migration from cigarettes).
Theme 4: Adjacent Growth / International (Embryonic)
| Initiative | Status | Revenue Impact |
|---|---|---|
| KT&G Collaboration | International modern oral, US non-nicotine (Korean ginseng), manufacturing efficiency | Import/export duty drawback is a margin lever; product revenue years away |
| Fumi Brand | Acquired; 40,000 retail locations in 7 international markets | Negligible currently |
| Ploom Heated Tobacco | PMTA + MRTPA filed with FDA (Aug 2025) | No revenue; FDA review timeline uncertain |
All adjacent initiatives are early stage with no material revenue contribution.
These provide optionality but are years from moving the needle.
Key Monitoring Items
on! PLUS National Launch
H1 2026
Share trajectory vs ZYN is the key swing factor
Cig Volume Trajectory
-7% Q4
Moderating from -11% Q1 2024; watch for -5-6%
Marlboro Share
39.8%
Sub-40% is a red flag; watch for stabilization
NJOY Modified ACE
TBD
Any return to market would be material upside
Score Rationale
| Factor | Direction | Notes |
|---|---|---|
| Oligopoly position in cigarettes | Strongly Positive | Dominant #1 with ~45% share. Marlboro alone ~40%. Consolidated market structure |
| Cigarette pricing power | Strongly Positive | 8.4% net price realization, 63%+ OCI margins -- world-class for consumer staples |
| Cigarette volume decline | Sig. Negative | -8-10% vs historical -3%. Accelerating driven by e-vapor competition |
| on! pouch positioning | Mod. Negative | Distant #2 to ZYN (4.5:1 volume gap). Share declining from 8.9% peak to 7.7% |
| on! PLUS catalyst | Mildly Positive | FDA authorized, positive feedback, but unproven at scale. H1 2026 national launch |
| E-vapor (NJOY) | Negative | ACE banned. $1.3B impairment. Effectively zero revenue. Will not return in 2026 |
| Regulatory moat (FDA) | Mildly Positive | on! PLUS and NJOY have FDA marketing granted orders -- competitive advantage |
| Dividend sustainability | Positive | 60 years of increases, 6.45% yield. Provides valuation floor for income investors |
| ESG / institutional exclusion | Structural Neg. | Creates a permanent valuation gap -- but also the source of the high yield |
6/10 — Altria scores a 6 reflecting a
declining oligopoly with extraordinary pricing power but a failing smoke-free transition.
Why 6 and not higher: The core business is a declining oligopoly. While pricing power is extraordinary, cigarette volume declines are accelerating at 2-3x historical rates (-8-10% vs -3-4%). ~88% of revenue is in this declining category. The smoke-free pivot is failing: NJOY is impaired and sidelined, on! is losing share ground to ZYN, and heated tobacco is years away. This is not a growth theme -- it is a managed decline with optionality.
Why 6 and not lower: Oligopoly pricing power is real and extraordinary. Smokable OCI grew despite 10% volume declines. Marlboro remains the single most dominant consumer brand in US tobacco. on! PLUS and FDA regulatory moats provide differentiation in a growing pouch category. The 6.45% dividend yield provides a floor, and the ESG exclusion discount creates value opportunity. Cigarette volume declines showed improvement in H2 2025 (-7% Q4 vs. -11% Q1 2024), and the import/export duty drawback is a genuine new margin lever.
Why 6 and not higher: The core business is a declining oligopoly. While pricing power is extraordinary, cigarette volume declines are accelerating at 2-3x historical rates (-8-10% vs -3-4%). ~88% of revenue is in this declining category. The smoke-free pivot is failing: NJOY is impaired and sidelined, on! is losing share ground to ZYN, and heated tobacco is years away. This is not a growth theme -- it is a managed decline with optionality.
Why 6 and not lower: Oligopoly pricing power is real and extraordinary. Smokable OCI grew despite 10% volume declines. Marlboro remains the single most dominant consumer brand in US tobacco. on! PLUS and FDA regulatory moats provide differentiation in a growing pouch category. The 6.45% dividend yield provides a floor, and the ESG exclusion discount creates value opportunity. Cigarette volume declines showed improvement in H2 2025 (-7% Q4 vs. -11% Q1 2024), and the import/export duty drawback is a genuine new margin lever.
Data sourced from Daloopa, Altria Q3 2025 and Q4 2025 earnings transcripts, and web research as of April 2026.